Medical/Pharmaceuticals

EmitBio Results Yield 99.99% Reduction of Delta in Human Tissue

New data proves technology neutralizes the Delta variant Third Human Trial Underway DURHAM, N.C., Sept. 1, 2021 /PRNewswire/ -- EmitBio, Inc., a life science company, today announced successful results from a new In Vitro Neutralization study of the Delta variant in human airway tissue. The stud...

2021-09-01 21:00 2750

EmitBio Results Yield 99.99% Reduction of Delta in Human Tissue

New data proves technology neutralizes the Delta variant Third Human Trial Underway DURHAM, N.C., Sept. 1, 2021 /PRNewswire/ -- EmitBio, Inc., a life science company, today announced successful results from a new In Vitro Neutralization study of the Delta variant in human airway tissue. The stud...

2021-09-01 21:00 1870

Seegene Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four COVID-19 Diagnostic Tests

SEOUL, South Korea, Sept. 1, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced on August 20 that it has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays. Combo Swab is a user-friendly...

2021-09-01 17:40 2381

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief Financial Officer

HOUSTON and SINGAPORE, Sept. 1, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the appointment of Josh House as Chief Financial Officer, effective immediately. Dr....

2021-09-01 17:00 1819

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 1, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) appl...

2021-09-01 13:05 3409

SK magic provides clean air and water to Malaysians at COVID-19 vaccine centers and hospitals

KUALA LUMPUR, Malaysia, Sept. 1, 2021 /PRNewswire/ -- In support of the National COVID-19 Immunisation Programme, SK magic, the leading home appliance company fromSouth Korea, equipped Covid-19 Vaccination Centres (CVCs) and treatment hospitals with its air and water purifiers to provide fresh and...

2021-09-01 11:49 3536

Zymo Research Receives CE Mark for New SafeCollect™ At-Home Sample Collection Kits

Self-collection devices designed for ease of use and safety IRVINE, Calif., Sept. 1, 2021 /PRNewswire/ -- Zymo Research announced today its new line of at-home sample collection kits has received CE marking for sale in the European Union (EU). TheSafeCollect™ Sample Collection Kits were designed...

2021-09-01 11:05 4089

SynForU(TM)-HerCare probiotics shows benefits to reduce vaginal yeast infection in pregnant women

KAOHSIUNG, Taiwan, Sept. 1, 2021 /PRNewswire/ -- The first clinical study which has been published in the Journal of Applied Microbiology documents that SynForU™-HerCare is effective in reducing vulvovaginal symptoms and recurrences of vaginal candidiasis (VC) in pregnant women.

2021-09-01 09:00 6088

MedAlliance Announces First Patient Enrolled in the 3,300 Patient Landmark Sirolimus DEB vs DES Study

GENEVA, Sept. 1, 2021 /PRNewswire/ -- MedAlliance is pleased to announce the enrollment of the first patient in the ground-breaking coronary randomized controlled study "SELUTION DeNovo". This study utilizes SELUTION SLR™, a novel sirolimus drug-eluting balloon [DEB], versus a limus drug-eluting ...

2021-09-01 08:00 3094

European Stroke Organisation Conference (ESOC) 2021: Non-traditional risk factors for heart attack and stroke rising more steeply in women, major study reveals

BASEL, Switzerland, Sept. 1, 2021 /PRNewswire/ -- Work stress, sleep disorders, and fatigue, regarded as non-traditional risk factors for heart attack and stroke, are rising more steeply amongst women than men, according to a new study presented today at the European Stroke Organisation (ESO) Con...

2021-09-01 06:00 3171

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell onAugust 31. Jacobio will collaborate with Hebecell to develop thenext-generation natural killer cell therapy based...

2021-08-31 22:05 5972

Jacobio Pharmaceuticals Announces 2021 Interim Results

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced its results for the first half of 2021. Investment in R&D for the clinical-stage biotech firm reached175 million yuan (approx. US$27 million) for the half year, up 146 percent ye...

2021-08-31 22:01 6354

Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

TAIPEI and SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its oral new drug, Silmitasertib, had received a positive feedbac...

2021-08-31 19:00 2161

Alithea Genomics Launches BRB-Seq Kits for High-Throughput RNA-Seq of Tissue, Cells and Blood Samples

LAUSANNE, Switzerland, Aug. 31, 2021 /PRNewswire/ -- Alithea Genomics, a rapidly growing player in the transcriptomics field, has announced today the launch of its first MERCURIUS BRB-seq kits, which enable high-throughput and cost-efficient RNA-seq library preparation from a wide range of RNA sa...

2021-08-31 19:00 3450

CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services

MONTRÉAL, Aug. 31, 2021 /PRNewswire/ -- CellCarta and Olink Proteomics AB announced today a strategic collaboration to offerOlink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies.

2021-08-31 19:00 3538

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

* Topical treatment safe and well tolerated in study of healthy volunteers * Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure * Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to com...

2021-08-31 18:00 2295

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021

* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...

2021-08-31 18:00 4008

Elekta Unity MR-Linac featured in 72 abstracts at European radiation oncology congress

MADRID, August 31, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of 72 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers worldwide, ref...

2021-08-31 14:21 2306

Harbour BioMed Reports 2021 Interim Results

CAMBRIDGE, Mass.and SUZHOU, China and ROTTERDAM, Netherlands, Aug. 31, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim...

2021-08-31 13:47 4324

HeartCare Medical Announces 2021 Interim Results

HONG KONG, Aug. 31, 2021 /PRNewswire/ -- Shanghai HeartCare Medical Technology Corporation Limited ("HeartCare Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 6609), a leading player in China's neuro-intervention market, announced its interim results for the si...

2021-08-31 13:11 4258
1 ... 631632633634635636637 ... 647